凌科药业（杭州）有限公司 Lingke Pharmaceutical Mediaroom

Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis

HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Lt...

2024-08-13 08:00 1814

Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001

BOSTON and HANGZHOU and SHANGHAI, China, March 22, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., L...

2024-03-22 08:00 2494

Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001

BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Lt...

2023-12-20 08:00 2603

Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB

HANGZHOU, China, Sept. 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referre...

2023-09-21 08:00 2620

Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis

HANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (referred to as "Lynk...

2023-08-23 08:00 3058

Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis

HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-08-09 08:00 3019

Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study

HANGZHOU, China, July 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2023-07-21 08:00 2914

Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing to Accelerate Clinical Development of Core Products

HANGZHOU, China, May 31, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-05-31 08:25 3981

Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004 in Phase Ib Clinical Study

HANGZHOU, China, May 25, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-05-25 08:00 4669

LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis

HANGZHOU, China, May 16, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2023-05-16 08:00 4101

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2023-04-04 20:00 2836

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2023-04-04 08:00 2773

Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis

HANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2022-12-05 08:00 2668

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2022-08-03 08:00 2675

Lynk Pharmaceuticals Announces the First Participant Dosed in Phase I Trial of LNK01004

HANGZHOU, China, July 29, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referre...

2022-07-29 10:00 3555

Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004

HANGZHOU, China, April 22, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referre...

2022-04-22 08:00 2993

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (...

2022-03-18 13:28 5390

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2022-02-28 08:00 3078

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred...

2022-01-19 08:00 3001

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001

HANGZHOU, China, Dec. 1, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred ...

2021-12-01 08:00 3480

Latest News